Turning Off STAT6 with a Targeted Degrader

While an attractive target for treating a range of human diseases and conditions, signal transducer and activator of transcription 6 (STAT6) has resisted drug discovery efforts for decades. This Viewpoint summarizes the discovery of a highly potent, selective STAT6 degrader with minimal off-target activity.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2025-02-20
DOI
https://doi.org/10.1021/acs.jmedchem.5c00415
Citations
1
Primary Topic
Immunodeficiency and Autoimmune Disorders
Type
article
Field-Weighted Citation Impact
0.80
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Turning Off STAT6 with a Targeted Degrader

Dehua Pei
1 citations
Journal of Medicinal Chemistry
Immunodeficiency and Autoimmune Disorders
0.80
article

Turning Off STAT6 with a Targeted Degrader

Dehua Pei
article en
1 citations

Abstract

While an attractive target for treating a range of human diseases and conditions, signal transducer and activator of transcription 6 (STAT6) has resisted drug discovery efforts for decades. This Viewpoint summarizes the discovery of a highly potent, selective STAT6 degrader with minimal off-target activity.

Journal of Medicinal ChemistryVol. 68(5)
The Ohio State University (US)
Openalex Percentile: Top 31%
Immunodeficiency and Autoimmune Disorders
0.80
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Turning Off STAT6 with a Targeted Degrader — Dehua Pei · Journal of Medicinal Chemistry (2025) | TGRS Research Map | TGRS